Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally

NCT04047420 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: TAF/EVG Insert

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]